耳穴压豆联合揿针促进经阴道自然腔道内镜手术行卵巢囊肿剥除术术后快速康复的随机对照研究

注册号:

Registration number:

ITMCTR2025001465

最近更新日期:

Date of Last Refreshed on:

2025-07-21

注册时间:

Date of Registration:

2025-07-21

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

耳穴压豆联合揿针促进经阴道自然腔道内镜手术行卵巢囊肿剥除术术后快速康复的随机对照研究

Public title:

A randomized controlled trial on the promotion of rapid recovery after ovarian cystectomy via transvaginal natural orifice transluminal endoscopic surgery by auricular point pressure seed and press needle therapy

注册题目简写:

耳穴压豆联合揿针促进vNOTES卵巢囊肿剥除术后快速康复的随机对照研究

English Acronym:

A randomized controlled trial on the promotion of rapid recovery after vNOTES ovarian cystectomy by auricular point pressure seed and press needle therapy

研究课题的正式科学名称:

耳穴压豆联合揿针促进经阴道自然腔道内镜手术行卵巢囊肿剥除术术后快速康复的随机对照研究

Scientific title:

A randomized controlled trial on the promotion of rapid recovery after ovarian cystectomy via transvaginal natural orifice transluminal endoscopic surgery by auricular point pressure seed and press needle therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈佳欣

研究负责人:

何丽

Applicant:

Chen Jiaxin

Study leader:

He Li

申请注册联系人电话:

Applicant telephone:

+86 159 8296 1477

研究负责人电话:

Study leader's telephone:

+86 138 8178 2966

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1624576141@qq.com

研究负责人电子邮件:

Study leader's E-mail:

helisc@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市青羊区日月大道1617号

研究负责人通讯地址:

四川省成都市青羊区日月大道1617号

Applicant address:

No. 1617 Riyue Avenue Qingyang District Chengdu Sichuan Province

Study leader's address:

No. 1617 Riyue Avenue Qingyang District Chengdu Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

611731

研究负责人邮政编码:

Study leader's postcode:

611731

申请人所在单位:

成都市妇女儿童中心医院

Applicant's institution:

Chengdu Women's and Children's Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

科研伦审2025(61)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

成都市妇女儿童中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chengdu Women and Children's Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/4/24 0:00:00

伦理委员会联系人:

唐丽娟

Contact Name of the ethic committee:

Tang Lijuan

伦理委员会联系地址:

成都市青羊区日月大道1617号

Contact Address of the ethic committee:

No. 1617 Riyue Avenue Qingyang District Chengdu Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 159 8230 3886

伦理委员会联系人邮箱:

Contact email of the ethic committee:

lunliwyh@163.com

研究实施负责(组长)单位:

成都市妇女儿童中心医院

Primary sponsor:

Chengdu Women and Children's Central Hospital

研究实施负责(组长)单位地址:

四川省成都市青羊区日月大道1617号

Primary sponsor's address:

No. 1617 Riyue Avenue Qingyang District Chengdu City Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

单位(医院):

成都市妇女儿童中心医院

具体地址:

成都市青羊区日月大道1617号

Institution
hospital:

Chengdu Women and Children's Central Hospital

Address:

No. 1617 Riyue Avenue Qingyang District Chengdu City Sichuan Province

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

卵巢良性肿瘤

研究疾病代码:

Target disease:

Benign ovarian tumor

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

旨在评估耳穴压豆法及揿针埋针的中医联合干预方式对使用VNOTES治疗卵巢良性肿瘤时在加速康复方面的优越性。

Objectives of Study:

The aim is to evaluate the superiority of the combined traditional Chinese medicine intervention methods of auricular point pressing bean method and press needle embedding needle in accelerating recovery when using VNOTES to treat benign ovarian tumors.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)年龄18-55周岁女性。 2) 经影像学检查(如超声、CT等)确诊为卵巢囊肿,且需行经阴道自然腔道内镜手术(vNOTES)剥除术的患者。 3) 符合vNOTES手术的适应证,包括但不限于囊肿大小、位置、患者一般情况等符合手术要求。 4) 能配合完成方案规定的访视及相关检查。‘ 5) 受试者自愿参加临床试验,并同意或监护人同意签署知情同意书。

Inclusion criteria

1)Female aged 18 to 55. 2) Patients diagnosed with ovarian cysts through imaging examinations (such as ultrasound CT etc.) and requiring transvaginal natural cavity endoscopic surgery (vNOTES) removal. 3) Meet the indications for vNOTES surgery including but not limited to the size and location of the cyst and the general condition of the patient meeting the surgical requirements. 4) Be able to cooperate in completing the visits and related inspections stipulated in the plan. ' 5) The subjects voluntarily participate in the clinical trial and agree or have their guardians agree to sign the informed consent form.

排除标准:

1) 入组前3个月内及计划在试验期间进行其他大型手术治疗者,或无法从任何此类手术的副作用中恢复者。 2) 患有严重的精神疾病,如精神分裂症、抑郁症等的患者。 3) 免疫缺陷病毒(HIV)抗体阳性者;丙型肝炎病毒(HCV)抗体阳性者;梅毒螺旋体抗体阳性;活动性肺结核且经研究者判断传染风险较大的患者。 4) 患有严重的全身性疾病,经研究者判断认为不适合进行手术治疗者。 5) 长期使用抗凝、抗血小板药物者,造血功能障碍或凝血功能障碍患者。 6) 筛选前3个月内参与过其他干预性临床试验者。

Exclusion criteria:

1) Those who undergo other major surgical treatments within 3 months before enrollment and are scheduled to do so during the trial or who are unable to recover from the side effects of any such surgery. 2) Patients with severe mental disorders such as schizophrenia depression etc. 3) Those with positive antibodies against the immunodeficiency virus (HIV); Those with positive hepatitis C virus (HCV) antibodies; Positive for Treponema pallidum antibody; Patients with active pulmonary tuberculosis who have been judged by researchers to have a relatively high risk of infection. 4) Those who suffer from severe systemic diseases and are determined by researchers to be unsuitable for surgical treatment. 5) People who have been using anticoagulant or antiplatelet drugs for a long time as well as patients with hematopoietic dysfunction or coagulation dysfunction. 6) Those who have participated in other interventional clinical trials within the three months prior to the screening.

研究实施时间:

Study execute time:

From 2025-04-24

To      2028-05-24

征募观察对象时间:

Recruiting time:

From 2025-06-29

To      2027-06-29

干预措施:

Interventions:

组别:

中医干预组

样本量:

48

Group:

Trial group

Sample size:

干预措施:

在常规护理下进行耳穴压豆及揿针中医联合治疗

干预措施代码:

Intervention:

Under routine care combined traditional Chinese medicine treatment of auricular point pressing and pressing acupuncture was carried out

Intervention code:

组别:

对照组

样本量:

48

Group:

Control group

Sample size:

干预措施:

进行常规护理,包括心理指导,进食指导、下床运动指导等

干预措施代码:

Intervention:

Carry out routine care, including psychological guidance, eating guidance, and guidance on getting out of bed for exercise, etc

Intervention code:

样本总量 Total sample size : 96

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

单位(医院):

成都市妇女儿童中心医院

单位级别:

三甲

Institution/hospital:

Chengdu Women and Children's Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

住院天数

指标类型:

次要指标

Outcome:

Hospitalization days

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

切口并发症

指标类型:

次要指标

Outcome:

Complications during surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Complications during surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后止痛药摄入情况

指标类型:

次要指标

Outcome:

Postoperative intake of painkillers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次下床活动时间

指标类型:

次要指标

Outcome:

The time of the first ambulation after the operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次排便情况

指标类型:

次要指标

Outcome:

The situation of the first defecation after the operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度

指标类型:

次要指标

Outcome:

patient satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次排气时间

指标类型:

主要指标

Outcome:

The time of the first postoperative exhaust

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

基线信息

指标类型:

附加指标

Outcome:

Baseline information

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛评分

指标类型:

次要指标

Outcome:

Postoperative pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 55
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

依照进入队列的顺序分配序号,并由软件随机和平均地分配到2个组中

Randomization Procedure (please state who generates the random number sequence and by what method):

Assign sequence numbers according to the order of entry into the queue and randomly and evenly allocate them to two groups by the software

盲法:

无法完全盲法,但对参与统计随访的研究者施盲

Blinding:

Unable to completely blind but blinded researchers participating in statistical follow-up

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman(http://www.medresman.org.cn/login.aspx)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman(http://www.medresman.org.cn/login.aspx)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统